Does SummaCare Cover Prolia? Denosumab Insurance Guide for 2025

How SummaCare Classifies Prolia Coverage

SummaCare processes Prolia under the medical benefit rather than the pharmacy benefit for most plan types. This distinction matters. Because denosumab is a physician-administered injectable given every six months in a clinical setting, it is billed using medical codes (typically CPT 96372 for the injection and HCPCS J0897 for the drug) rather than filled at a retail pharmacy.

Coverage under the medical benefit means your cost-sharing follows medical copay or coinsurance rules, not prescription drug tier pricing. For SummaCare HMO and PPO plans, this usually means the injection is subject to your plan's specialist visit copay or outpatient procedure coinsurance after you meet any applicable deductible. Members on SummaCare Medicare Advantage plans may see different cost-sharing structures, with many Medicare Advantage plans covering Part B drugs like Prolia at 20% coinsurance after the Part B deductible of $257 (2025 rate) is met 1.

SummaCare's formulary documents and clinical coverage policies align with standard commercial insurance practices for biologic osteoporosis therapies. The Endocrine Society's 2020 clinical practice guideline recommends denosumab as a first-line or second-line option for postmenopausal women at high fracture risk, supporting its classification as a medically necessary treatment when criteria are met.

Prior Authorization Requirements

SummaCare requires prior authorization before approving Prolia. Expect this process. Your prescribing physician will need to submit clinical documentation proving medical necessity, and the insurer reviews this against its coverage criteria before issuing approval.

Standard prior authorization criteria for Prolia across most SummaCare plans include: a confirmed diagnosis of osteoporosis (DXA T-score of -2.5 or lower at the hip, femoral neck, or lumbar spine), documented intolerance or contraindication to oral bisphosphonates, or failure to respond to an adequate trial of oral bisphosphonate therapy. "Adequate trial" typically means 12 months of compliant use with continued bone loss or a new fracture during treatment.

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo over 36 months 2. These data form the clinical backbone for insurer coverage policies nationwide. SummaCare may also approve Prolia for men with osteoporosis at high fracture risk, patients on long-term glucocorticoid therapy (prednisone 7.5 mg/day or equivalent for 3+ months), and patients receiving androgen deprivation therapy for prostate cancer or aromatase inhibitor therapy for breast cancer 3.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "Denosumab represents a significant advance for patients who cannot take or do not respond to bisphosphonates, offering consistent fracture risk reduction with a convenient twice-yearly dosing schedule."

The prior authorization turnaround time is typically 5 to 15 business days. Urgent requests can be expedited.

Step Therapy: What You Need to Try First

Most SummaCare plans enforce step therapy for Prolia. This means your doctor must document that you tried (and failed or could not tolerate) a generic oral bisphosphonate before the plan will authorize denosumab.

The most common first-step drugs are alendronate (generic Fosamax, roughly $4 to $15/month) and risedronate (generic Actonel). SummaCare's step therapy protocol generally requires 3 to 12 months of documented bisphosphonate use, depending on the specific plan. Exceptions exist for patients with contraindications to oral bisphosphonates: esophageal disorders such as Barrett's esophagus or stricture, inability to remain upright for 30 minutes after dosing, documented GI intolerance, severe renal impairment (creatinine clearance <35 mL/min), or hypocalcemia 4.

If your physician documents any of these contraindications, SummaCare can waive the step therapy requirement and approve Prolia as a first-line agent. The American Association of Clinical Endocrinology (AACE) 2020 guidelines support initiating denosumab without prior bisphosphonate use in patients classified as "very high fracture risk," defined as a recent osteoporotic fracture within the past 12 months, fractures while on approved osteoporosis therapy, multiple fractures, T-score below -3.0, or high FRAX probability 5.

Estimating Your Out-of-Pocket Cost

Prolia's wholesale acquisition cost (WAC) is approximately $1,800 to $2,000 per injection. Your actual out-of-pocket expense with SummaCare depends on several variables: your plan type, whether you have met your annual deductible, and how your plan structures medical benefit cost-sharing.

For SummaCare commercial PPO and HMO members who have met their deductible, the typical cost per Prolia injection ranges from $0 (for plans with fixed specialist copays that cover office-administered drugs) to $150 (for plans with 20% coinsurance on outpatient procedures). Members who have not yet met their deductible could owe the full contracted rate, which is typically lower than WAC due to negotiated discounts between SummaCare and Amgen.

SummaCare Medicare Advantage members follow Medicare Part B cost-sharing rules for physician-administered drugs. After the annual Part B deductible ($257 in 2025), members typically pay 20% coinsurance. For a Prolia injection billed at the Medicare allowable rate, this translates to roughly $250 to $350 per injection before any supplemental coverage or plan-specific copay caps apply 6.

Amgen's Prolia patient assistance programs can reduce costs further. The ENBREL/Prolia Support program and Amgen Safety Net Foundation offer copay assistance cards (for commercially insured patients, reducing copays to as low as $0) and free drug programs for uninsured or underinsured patients meeting income requirements.

What to Do If SummaCare Denies Coverage

A denial is not the end. SummaCare members have multiple appeal pathways, and a significant percentage of initial denials are overturned on appeal when proper documentation is submitted.

The first step after a denial is requesting the specific reason in writing. Common denial reasons include: missing prior authorization, incomplete documentation of bisphosphonate trial, DXA scan not on file, or diagnosis not meeting coverage criteria. Your physician can address each of these directly.

For a first-level appeal, your doctor should submit a letter of medical necessity that includes your DXA T-scores, fracture history, bisphosphonate trial dates and outcomes (or documented contraindications), FRAX score, and relevant comorbidities. Citing clinical guideline support strengthens the appeal. The Endocrine Society and AACE both recommend denosumab for patients who meet specific clinical thresholds 7.

If the first appeal fails, SummaCare offers external review through an independent review organization (IRO). Ohio insurance regulations (Ohio Revised Code 3922.01 et seq.) guarantee the right to external review for adverse benefit determinations. Data from state insurance departments suggest that approximately 40% to 60% of external reviews for specialty biologic medications result in overturned denials.

Dr. Andrea Singer, director of bone densitometry at MedStar Georgetown University Hospital and past president of the National Osteoporosis Foundation, has noted: "Persistence with the appeals process is key. Most denials for denosumab stem from incomplete paperwork rather than genuine clinical ineligibility."

SummaCare Medicare Advantage vs. Commercial Plans

Coverage mechanics differ between SummaCare's Medicare Advantage products and its commercial (employer-sponsored) plans. Understanding which plan type you have determines both the approval pathway and your cost exposure.

SummaCare Medicare Advantage plans cover Prolia under Medicare Part B because it is a physician-administered drug. Part B drug coverage follows national coverage determinations (NCDs) and local coverage determinations (LCDs) issued by Medicare Administrative Contractors. The LCD for denosumab (L38637) outlines specific coverage criteria including DXA-confirmed osteoporosis and documented clinical need 8. Medicare Advantage plans cannot impose coverage restrictions more stringent than Original Medicare, though they may add prior authorization requirements within CMS guidelines.

Commercial SummaCare plans have more flexibility in setting coverage criteria. Step therapy requirements may be stricter, and the list of acceptable "first-step" drugs may be narrower. Some employer-sponsored SummaCare plans also place Prolia on a specialty tier with higher coinsurance (25% to 33%) rather than processing it under standard medical benefit cost-sharing.

A 2021 analysis published in the Journal of Managed Care & Specialty Pharmacy found that prior authorization requirements for denosumab varied substantially across commercial insurers, with approval rates ranging from 72% to 91% on initial submission 9. SummaCare's approval rates have not been publicly reported, but regional Ohio insurers generally fall within this range.

Prolia vs. Covered Alternatives on SummaCare

If Prolia is denied or cost-prohibitive, SummaCare covers several alternative osteoporosis therapies at different cost-sharing levels.

Generic alendronate (70 mg weekly) is the lowest-cost option on most SummaCare formularies, typically classified as Tier 1 with copays of $0 to $15 for a 90-day supply. Risedronate and ibandronate (monthly oral dosing) sit on Tier 2 for most plans. Zoledronic acid (Reclast), a once-yearly IV bisphosphonate, is covered under the medical benefit similarly to Prolia and may require prior authorization but often faces less stringent step therapy requirements since it is itself a bisphosphonate 10.

For anabolic agents, teriparatide (Forteo) and abaloparatide (Tymlos) are covered by some SummaCare plans but typically require prior authorization and documentation of severe osteoporosis (T-score below -3.5 or multiple vertebral fractures). Romosozumab (Evenity), the newest anabolic agent, has the most restrictive coverage criteria and highest out-of-pocket costs.

The HORIZON-PFT trial (N=7,765) showed that zoledronic acid 5 mg IV annually reduced vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years 10. These efficacy numbers are comparable to Prolia's FREEDOM trial results, making zoledronic acid a reasonable covered alternative when denosumab is inaccessible.

Stopping Prolia: Insurance Implications You Should Know

Discontinuing Prolia carries unique clinical risks that have insurance coverage implications. Unlike bisphosphonates, which deposit in bone and continue exerting antiresorptive effects for months to years after discontinuation, denosumab's effects reverse rapidly. Bone turnover markers rebound above baseline within 3 to 6 months of a missed dose, and multiple vertebral fractures have been reported in patients who discontinued denosumab without transitioning to another antiresorptive 11.

The FDA issued a Drug Safety Communication in 2022 adding a boxed warning about this rebound vertebral fracture risk. This warning is clinically significant for insurance purposes: if you switch SummaCare plans or lose coverage, you need a transition plan. Your physician should document the necessity of uninterrupted denosumab therapy, or arrange a bisphosphonate bridge (typically one dose of zoledronic acid 5 mg IV) to prevent the rebound effect.

SummaCare members considering plan changes during open enrollment should verify Prolia coverage on the new plan before switching. A gap in treatment is not just inconvenient. It is dangerous.

How to Get Prolia Approved Faster

Speed matters when you have active osteoporosis. These concrete steps can reduce the time from prescription to injection.

Ask your physician to submit prior authorization proactively, before scheduling the injection appointment. Include all supporting documents in the initial submission: recent DXA scan (within the past 24 months), documentation of prior bisphosphonate use or contraindication, FRAX score calculation, relevant lab work (calcium, vitamin D, renal function), and a clear statement of medical necessity citing guideline recommendations.

Contact SummaCare's prior authorization department directly at the number on the back of your member ID card to confirm receipt of the submission and ask about expected turnaround. If you have not received a determination within 15 business days, call again and request escalation. For urgent clinical situations (recent fracture, rapidly declining bone density), ask your physician to submit an urgent prior authorization request, which SummaCare must process within 72 hours under Ohio insurance regulations.

The average total body bone mineral density loss in untreated postmenopausal osteoporosis is 1% to 2% per year 12. Each month of delay in starting treatment represents continued fracture risk accumulation.